Senti Biosciences Holdings (SNTI) Amortizatization of Intangibles (2022 - 2023)
Senti Biosciences Holdings (SNTI) posted quarterly Amortizatization of Intangibles of $117000.0 for Q3 2023, down 69.21% quarter-over-quarter from $380000.0 in Q2 2023.
Senti Biosciences Holdings (SNTI) Amortizatization of Intangibles (2022 - 2023) Analysis & Trends
Senti Biosciences Holdings' Amortizatization of Intangibles history runs 2 years deep, the most recent figure standing at $117000.0 for Q3 2023.
- In Q3 2023, Amortizatization of Intangibles changed N/A year-over-year to $117000.0; the TTM figure through Jun 2024 stood at $117000.0 (down 91.06% YoY), while the FY2023 annual figure was $1.1 million, up 200.28% from the prior year.
- Amortizatization of Intangibles for Q3 2023 stood at $117000.0, down from $380000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $572000.0 in Q1 2023, with the low at $117000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 117,000.00 |
| Sep 30, 2023 | 117,000.00 |
| Jun 30, 2023 | 380,000.00 |
| Jun 30, 2023 | 380,000.00 |
| Mar 31, 2023 | 572,000.00 |
| Mar 31, 2023 | 572,000.00 |
| Dec 31, 2022 | 356,000.00 |
| Dec 31, 2022 | 356,000.00 |